Microproteinuria in patients with inflammatory bowel disease: Is it associated with the disease activity or the treatment with 5-aminosalicylic acid?

World Journal of Gastroenterology

Volumn 12, Issue 5, 2006, Pages 739-746

  Poulou, Androniki C ^a   Goumas, Konstantinos E ^a   Dandakis, Dimitrios C ^a   Tyrmpas, Ioannis ^a   Panagiotaki, Maria ^a   Georgouli, Androniki ^a   Soutos, Dimitrios C ^a   Archimandritis, Athanasios ^b  

^a RED CROSS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

5 aminosalicylic acid; Inflammatory bowel disease; Microproteinuria

Indexed keywords

ALBUMIN; AZATHIOPRINE; BETA 2 MICROGLOBULIN; CREATININE; MESALAZINE; N ACETYL BETA GLUCOSAMINIDASE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PREVALENCE; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; SMOKING HABIT; ULCERATIVE COLITIS;

EID: 33644886293     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i5.739     Document Type: Article

References (47)

1. Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VW (EDS). Inflammatory bowel disease (3rd edition) Churchill Livingstone New York, 1997
2. Katsanos KH, Tsianos EV. The kidney in inflammatory bowel disease. Annals Gastroenterol 2002; 15: 41-52
3. Goerig M. Renal Complications and Manifestations in Crohn's Disease. In Lingua Med-Publishers Ltd. Extraintestinal Manifestations of Crohn's Disease 1992; 57-60
4. Pardi DS, Tremain WJ, Sandborn WJ, Mc Carthy JT. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93: 504-514
5. Fitchen JH. Amyloidosis and granulomatous ileocolitis. Reagression after surgical removal of the involved bowel. N Engl J Med 1975; 292: 352-353.
6. Moayyedi P, Fletcher S, Harnden P, Axon AT, Brownjohn A. Mesangiocapillary glomerulonephritis associated with ulcerative colitis: case reports of two patients. Nephrol Dial Transplant 1995; 10: 1923-1924.
7. Wilcox GM, Aretz HT, Roy MA, Roche JK. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology 1990; 98: 786-791
8. Dhiman RK, Poddar U, Sharma BC, Arora P, Saraswat VA, Pandey R, Naik SR. Membranous glomerulonephritis in association with ulcerative colitis. Indian J Gastroenterol 1998; 17: 62
9. McCallum D, Smith L, Harley F, Yiu V. IgA nephropathy and thin basement membrane disease in association with Crohn disease. Pediatr Nephrol 1997; 11: 637-640
10. Archimandritis AJ, Weetch MS. Kidney granuloma in Crohn's disease. BMJ 1993; 307: 540-541
11. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1-6
12. CHAPIN LE, SCUDAMORE HH, BAGGENSTOSS AH, BARGEN JA. Regional enteritis: associated visceral changes. Gastroenterology 1956; 30: 404-415
13. Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 2001; 15: 1131-1137
14. Mahmud N, Stinson J, O'Connell MA, Mantle TJ, Keeling PW, Feely J, Weir DG, Kelleher D. Microalbuminuria in inflammatory bowel disease. Gut 1994; 35: 1599-1604
15. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut 1992; 33: 1348-1352
16. Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001; 15: 363-369
17. Kreisel W, Wolf LM, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8: 461-468
18. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31: 673-689
19. Price RG, Whiting PH. Urinary enzymes and nephrotoxicity in humans. In:Jung K, Mattenheimer H, Burchardt U, eds. Urinary Enzymes. Berlin: Springer-Verlag, 1992: 203-221
20. Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, Raedler A, Kruis W. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997; 40: 761-766
21. Gabriel R. Time to scrap creatinine clearance? Br Med J (Clin Res Ed) 1986; 293: 1568
22. Markantonis SL, Agathokleous-Kioupaki E. Can two-, four- or eight-hour urine collections after voluntary voiding be used instead of twenty-four-hour collections for the estimation of creatinine clearance in healthy subjects? Pharm World Sci 1998; 20: 258-263
23. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-86
24. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
25. Taguchi Y, Miyaoka M, Saito T. Endoscopic diagnosis of ulcerative colitis. Nippon Rinsho 1999; 57: 2453-2456
26. Osberg I, Chase HP, Garg SK, DeAndrea A, Harris S, Hamilton R, Marshall G. Effects of storage time and temperature on measurement of small concentrations of albumin in urine. Clin Chem 1990; 36: 1428-1430
27. Schweizer RT, Moore R, Bartus SA, Bow L, Hayden J. Beta 2-microglobulin monitoring after renal transplantation. Transplant Proc 1981; 13: 1620-1623
28. Yakata M, Sugita O, Sakai T, Uchiyama K, Wada K. Urinary enzyme determination and its clinical significance. C. Enzyme derived from the kidney tubular epithelium--N-acetyl-beta-D-glucosaminidase. 4. Preclinical evaluation of the urinary NAG activity and changes in renal diseases. Rinsho Byori 1983; Spec No 56: 90-101
29. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467-472
30. Mahmud N, O'Connell MA, Stinson J, Goggins MG, Weir DG, Kelleher D. Tumour necrosis factor-alpha and microalbuminuria in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 215-219
31. Bonnet J, Lemman M, Prunat A. Renal function in patients with inflammatory bowel disease on long term mesalamine or olsalazine. Gastroenterology 1995; 108: A 786 (abstract)
32. Zehnter E, Dorhofer H, Ziegenhagen DJ, Scheurlen C, Baldamns CA, Kruis W. Renal damage in patients with IBD treated with 5-aminosalicylic acid and sulphasalazine. Gastroenterology 1994; 100: A264(abstract)
33. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084
34. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in noninsulin-dependent diabetics. Diabet Med 1984; 1: 17-19
35. Gosling P, Shearman CP. Increased levels of urinary proteins: marker of vascular permeability? Ann Clin Biochem 1988; 25(suppl): 150-151
36. Yi ES, Ulich TR. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol 1992; 140: 659-663
37. Mahmud N, McDonald GS, Kelleher D, Weir DG. Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut 1996; 38: 99-103
38. Biddle W, Miner PB. Evaluation of potential nephrotoxicity of oral 5-ASA treatment of patients with ulcerative colitis abstract. Gastroenterology 1989; 96: A44
39. Winstanley PA, Young JB, Axon AT, Brownjohn AM, Cooper EH. Renal proximal tubular dysfunction in Crohn's disease. Br Med J (Clin Res Ed) 1984; 288: 1612-1613
40. Maeda M, Watanabe N, Neda H, Yamauchi N, Okamoto T, Sasaki H, Tsuji Y, Akiyama S, Tsuji N, Niitsu Y. Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992; 14: 451-461
41. Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993; 341: 711-714
42. Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 1992; 102 ( Pt 4): 821-832
43. Sninsky C, Hanauer S, Powers B, Robinson M, Mayel F, Elson C, et al. Sensitive markers of renal dysfunction are elevated in chronic ulcerative colitis (abstract). World Congress of Gastroenterology, 1994: A 1778 P
44. Srivastava ED, Russell MA, Feyerabend C, Rhodes J. Effect of ulcerative colitis and smoking on rectal blood flow. Gut 1990; 31: 1021-1024
45. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-1854
46. Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123-1128
47. Roth M, Steinhauer HB, Gerok W, Schölmerich J. Beta2 microglobulin and prostagladin E2 excretion is increased in patients with inflammatory bowel diseases- a new extraintestinal manifestation (abstract). Gastroenterology 1991; 100: A 245